Regeneron

Market Access

Dupixent's seventh indication is chronic hives, where a new treatment hasn't been approved since Novartis's Xolair in 2014

Digital

At Reuters Pharma USA, presenters showed off an AI aimed at reimagining the complex process of pharmaceutical naming.

News

Regeneron has refiled its CD20xCD3 bispecific odronextamab for lymphoma with the FDA, which was rejected last year, but is seeking a narrower label.

News

Ten out of 11 children with congenital deafness treated with a gene therapy developed by Regeneron have seen "notable" improvements in hearing.

News

The FDA is scheduled to deliver a verdict on Sanofi and Regeneron's Dupixent for rare autoimmune skin disorder bullous pemphigoid in June.

News

Regeneron and Illumina have joined a major investment in health data specialist Truveta that will support the creation of a major new genome project.